Skip to main content

Table 3 Clinical trials with immune checkpoints therapy in liver cancers

From: Immune checkpoint therapy in liver cancer

Cancer type Number Study arms Stage Status Design Primary outcome Estimated completion Trial NCT
HCC 35 Nivolumab (anti PD-1 Ab) + LRT (Yttrium 90Y glass microspheres) Phase 1 Recruiting Single Group Assignment July 2019 July 2019 NCT02837029
HCC 154 PDR001 (anti PD-1 Ab) + NIS793 (anti TGF-b Ab) Phase 1 Recruiting Non-Randomized January 12, 2020 January 12, 2020 NCT02947165
HCC 114 Durvalumab (anti PD-1L Ab) + ramucirumab (anti-VEGF-R2 Ab) Phase 1 Recruiting Non-Randomized March 2018 September 2018 NCT02572687
HCC 51 Durvalumab (anti PD-1 L Ab) + AZD4635 Phase 1 Recruiting Non-Randomized November 9, 2017 November 9, 2017 NCT02740985
HCC 61 Tremelimumab (anti CTLA-4 Ab) Phase 1 Active, not recruiting Non-Randomized December 31, 2017 December 31, 2018 NCT01853618
Liver cancer 60 Ipilimumab (anti CTLA-4 Ab) + MGN1703 (Toll-like receptor agonist) Phase 1 Recruiting Non-Randomized May 2019 May 2019 NCT02668770
HCC 120 Ipilimumab (anti CTLA-4 Ab) + stereotactic body radiation Phase 1 Recruiting Randomized August 2019 August 2019 NCT02239900
HCC 75 Nivolumab (anti PD-1 Ab) + galunisertib (TGF-b inhibitor) Phase 1/2 Recruiting Non-Randomized April 2018 March 2019 NCT02423343
HCC 620 Nivolumab (anti PD-1 Ab) + ipilimumab (anti CTLA-4 Ab) Phase 1/2 Recruiting Non-Randomized July 22, 2018 July 9, 2019 NCT01658878
HCC 108 PDR001 (anti PD-1 Ab) + INC280 (c-Met inhibitor) Phase 1/2 Recruiting Non-Randomized December 24, 2018 December 24, 2018 NCT02795429
HCC 50 Prembrolizumab (anti PD-1 Ab) + dendritic cells, cytokine-induced killer cells Phase 1/2 Recruiting Single Group Assignment September 2019 October 2019 NCT02886897
HCC 15 Prembrolizumab (anti PD-1 Ab) Phase 1/2 Recruiting Single Group Assignment December 2019 December 2019 NCT02940496
HCC 50 Nivolumab (anti PD-1 Ab) + CC-122 (immunostimulatory pathway modifier) Phase 1/2 Recruiting Single Group Assignment June 23, 2020 June 23, 2020 NCT02859324
HCC 90 Durvalumab (anti PD-1 L Ab), Tremelimumab (anti CTLA-4 Ab) + LRT Phase 1/2 Recruiting Non-Randomized April 30, 2020 April 30, 2021 NCT02821754
HCC 620 Nivolumab (anti PD-1 Ab), Nivolumab + Ipilimumab, Nivolumab + cabozantinib, Nivolumab + Ipilimumab + cabozantinib Phase 1/2 Recruiting Non- Randomized September 4, 2018 July 9, 2019 NCT01658878
HCC 28 Pembrolizumab (Keytruda) (anti PD-1 Ab) Phase 2 Recruiting Single Group Assignment April 2018 April 2019 NCT02658019
HCC 440 Durvalumab (anti PD-1 L Ab) + Tremelimumab (anti CTLA-4 Ab) Phase 2 Recruiting Randomized March 20, 2020 March 20, 2020 NCT02519348
HCC 726 Nivolumab (anti PD-1 Ab) Phase 3 Recruiting Randomized October 1, 2018 June 22, 2019 NCT02576509
HCC 408 Prembrolizumab (anti PD-1 Ab) Phase 3 Active, not recruiting Randomized February 1, 2019 February 1, 2019 NCT02702401
HCC 1200 Durvalumab (anti PD-1 L Ab) + tremelimumab (anti CTLA-4 Ab) Phase 3 Not yet recruiting Randomized February 27, 2020 March 29, 2021 NCT03298451